FY24: Logistics & IT, digital innovation shine bright

12/03/25 -"Galenica reported a strong FY 2024 performance, with sales increasing by 4.7%, driven by growth across all segments except ‘at-home’ pharmacies. Adjusted EBIT increased by 10.3%, ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

12/03/25

Download

You may also be interested by these reports :

16/06/26

Redcare Pharmacy

Redcare accelerates growth, improves profitability and raises its guidance

09/06/26

Ferguson

We have updated our financial model to reflect Ferguson’s change in fiscal year-end from 31 July to 31 December. Following a five-month transition ...

03/06/26

Inditex

Inditex commenced FY26 robustly, with sales and profitability slightly surpassing consensus expectations. The Spring/Summer collections were ...

03/06/26

Asos

We have incorporated FY25 figures and revised our forecasts to reflect the weaker than anticipated top line development. While the group’s ongoing ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue